Epimax Excetra Cream

Epimax Excetra Cream is a medical emollient manufactured in the United Kingdom. It is specifically formulated for the daily management of dry skin conditions such as eczema and psoriasis, acting as both a leave-on moisturizer and a soap substitute.

The Epimax brand was developed by Aspire Pharma Limited, a British pharmaceutical company founded in 2009. The brand's focus is on providing cost-effective, clinically proven dermatological solutions to healthcare systems and consumers.

Ownership of the brand transitioned in 2022 when H.I.G. Capital, a global private equity firm, acquired a majority stake in Aspire Pharma. As of 2024 and beyond, Aspire Pharma remains the key operating entity, continuing its expansion within the European pharmaceutical market while headquartered in Petersfield, United Kingdom.